Fig. 1 · Structure

Documents & Downloads

LOR-253

Cat. No. A13838 CAS 916151-99-0

MTF-1 inhibitor

LOR-253 is a small molecule inhibitor of human metal-regulatory transcription factor 1 (MTF-1).

In Stock

Publications for LOR-253

1 publication citing this product

  1. Balaji Chandrasekaran, .et al. , Int J Biol Sci, 2025, May 27;21(8):3614-3630 PMID: 40520016

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In human lung fibroblasts, APTO-253 suppression of TGF-β-induced α-SMA expression was substantially attenuated by KLF4 knockdown. This supports a contribution from KLF4 inducibility in this model, without establishing an exclusive mechanism or direct KLF4 binding. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

LOR-253 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of LOR-253 from 3 published references. In vitro models include cadmium-transformed human BPH1 prostate cells. In vivo models include wild-type female C57BL/6 mice with single-bleomycin pulmonary fibrosis.

LOR-253 In Vitro Studies

LOR-253 had a reported 24-hour cell-viability IC50 of 73 µM in cadmium-transformed BPH1 prostate cells. This cellular endpoint should not be interpreted as a biochemical MTF1 inhibition constant. [2]

In a 5-day viability assay, BRCA2-deficient HCT116 B18 and B46 clones were more sensitive to APTO-253 than BRCA2-proficient HCT116 cells. The result supports genotype-dependent sensitivity in this paired-cell system. [3]

APTO-253 pretreatment reduced TGF-β-induced α-SMA mRNA in control MRC5 lung fibroblasts, with a smaller suppressive effect in KLF4-knockdown cells. The experiment used 250 nM APTO-253 for 36 hours before a 48-hour TGF-β challenge. [1]

LOR-253 concentration response in CTBPH1 cells

Cell-based study · Cadmium-transformed human BPH1 prostate cells (CTBPH1) [2]

The authors report a 24-hour cellular viability IC50 of 73 µM. This is a model-specific cellular endpoint, not a biochemical MTF1 inhibitory potency.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CTBPH1 cell viability after 24 hoursIC50 73 µM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration series shown from 0 to 100 µM
Exposure duration
24 h
Method
Cell treatment with LOR-253
Reported limits
Drug-series assay chemistry, vehicle and IC50 fitting method are not explicit. Shared statistics states triplicates and mean ± SD, without identifying independent biological repeats for this panel.
Methods and source locations

Compound reported in the paper: LOR-253; Compound label in the paper: LOR-253

Applicable to the named SKU at compound level; no claim that the current AdooQ lot was tested.

Results: Cadmium fails to restore ZIC2 function in MTF1 knockdown CTBPH1 cells; Figure 3B; Materials and Methods: Cell lines and reagents, Viability assay

CTBPH1 cell viability after 24 hours: Cell viability concentration response in Figure 3B, normalized to the zero-concentration condition. The Viability assay methods describe trypan blue for shRNA experiments but do not explicitly establish the assay used for the LOR-253 series. Shared Statistical analysis states cell-culture experiments were performed in triplicates and data are mean ± SD; the drug panel does not identify independent biological repeats. — Results: Cadmium fails to restore ZIC2 function in MTF1 knockdown CTBPH1 cells; Figure 3B; Materials and Methods: Cell lines and reagents, Viability assay

BRCA2-deficient HCT116 clones show greater APTO-253 sensitivity

Cell-based study · Human HCT116 BRCA2-proficient cells and BRCA2-deficient B18 and B46 clones [3]

After 5-day treatment, both BRCA2-deficient clones showed lower viable-cell fractions across the APTO-253 response series than the BRCA2-proficient cells. Olaparib was tested separately as a comparator.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Genotype-associated difference in viable-cell fractionQualitative concentration-response comparison Greater APTO-253 sensitivity in B18 and B46 than BRCA2-proficient HCT116[3]

Literature-Reported Treatment Conditions

Treatment concentration
APTO-253 series plotted over 0–0.4 µmol/L
Exposure duration
5 days
Method
Separate concentration-response viability assays
Co-treatment
None; olaparib was a separate comparator, not a combination.
Reported limits
Exact IC50 values, replicate count for panel E and vehicle identity for this response series are not specified in the acquired main-text assay description/caption.
Methods and source locations

Compound reported in the paper: APTO-253; Compound label in the paper: APTO-253

Parent-compound cellular result; no iron-complex-to-parent dose conversion or current AdooQ lot validation.

Figure 3E and caption; Results: BRCA1/2-deficient cells are hypersensitive to APTO-253; Materials and Methods: Drugs and reagents, Cell types and culture, Cytotoxicity study

Genotype-associated difference in viable-cell fraction: 5-day CellTiter 96 AQueous one solution MTS assay; Figure 3E. The curves report percent of vehicle control and vertical bars indicate ±SEM. No exact IC50 is extracted. — Figure 3E and caption; Results: BRCA1/2-deficient cells are hypersensitive to APTO-253; Materials and Methods: Drugs and reagents, Cell types and culture, Cytotoxicity study

KLF4 knockdown attenuates the fibroblast response to APTO-253

Cell-based study · Control and CRISPR-mediated KLF4-knockdown MRC5 human lung fibroblasts stimulated with TGF-β [1]

APTO-253 pretreatment reduced TGF-β-induced α-SMA mRNA in control fibroblasts. This suppression was substantially attenuated, rather than abolished, in KLF4-knockdown cells, supporting a contribution from KLF4 inducibility.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TGF-β-induced α-SMA mRNA in control versus KLF4-knockdown fibroblastsqPCR response Suppression by APTO-253 was substantially attenuated in KLF4-knockdown cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
APTO-253 250 nM; subsequent TGF-β 2 ng/mL (Methods default concentrations)
Exposure duration
APTO-253 for 36 h, followed by TGF-β stimulation for 48 h
Method
Pretreatment and subsequent differentiation challenge
Co-treatment
TGF-β is the experimental differentiation stimulus.
Reported limits
The supplemental panel does not specify vehicle identity or whether APTO-253 was removed when TGF-β was added.
Methods and source locations

Compound reported in the paper: APTO-253; Compound label in the paper: APTO-253

Nominal APTO-253 research effects in this cell model; no current AdooQ lot or exact salt-state equivalence validation.

Supplemental Figure 8 (official supplemental PDF p. 9); Results: APTO-253–mediated suppression of fibroblast activation depends on KLF4 inducibility; Methods: Reagents, fibroblast differentiation, qPCR, Statistics

TGF-β-induced α-SMA mRNA in control versus KLF4-knockdown fibroblasts: qPCR with human GAPDH reference; Supplemental Figure 8: mean ± SEM of 3 independent experiments; *P < 0.05, 2-way ANOVA. No fold values estimated from bars. — Supplemental Figure 8 (official supplemental PDF p. 9); Results: APTO-253–mediated suppression of fibroblast activation depends on KLF4 inducibility; Methods: Reagents, fibroblast differentiation, qPCR, Statistics

LOR-253 In Vivo Studies

In a single-bleomycin mouse model, APTO-253 treatment initiated on day 9 reduced lung hydroxyproline and histological fibrosis at day 21 relative to bleomycin plus vehicle. This self-limiting injury model does not establish efficacy in chronic human pulmonary fibrosis. [1]

APTO-253 attenuates fibrosis in a single-bleomycin mouse model

Animal study · Wild-type female C57BL/6 mice with single-bleomycin pulmonary fibrosis [1]

APTO-253 initiated during the fibrotic phase reduced day-21 lung hydroxyproline and histological fibrosis relative to bleomycin plus vehicle. This injury model is self-limiting and does not demonstrate clinical efficacy or durable reversal of chronic disease.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Lung hydroxyproline at day 21Between-group reduction Lower with APTO-253 than bleomycin + vehicle; P < 0.05[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Every other day beginning on day 9 after bleomycin
Treatment course
Figure 6A shows dosing arrows on days 9, 11, 13, 15, 17 and 19 and sacrifice on day 21. Methods describes treatment beginning day 9 until sacrifice; no extra day-21 dose is inferred.
Vehicle
Corn oil
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Bleomycin + APTO-253
25 mg/kg APTO-253
Bleomycin + vehicle; saline + vehicle and saline + APTO-253 groups were also included.Reduced lung hydroxyproline and less trichrome-positive fibrotic distortion than bleomycin + vehicle at day 21. The saline-treated groups showed no observable effect on these lung endpoints.[1]
Bleomycin + APTO-253
Model: Wild-type female C57BL/6 mice, 8 weeks old; single-bleomycin pulmonary fibrosis model
Reported limits: Caption reports n = 5–8 mice per group across Figure 6 quantitative panels; it does not give a panel-C-specific sample-size table. No exact hydroxyproline values are inferred from the graph.
Methods and source locations

Compound reported in the paper: APTO-253; Compound label in the paper: APTO-253

Preclinical pulmonary fibrosis model; no anticancer, human efficacy or current AdooQ lot-validation inference.

Figure 6A-C and caption; Results: Therapeutic administration of APTO-253 protects mice from bleomycin-induced pulmonary fibrosis; Methods: Mice, Bleomycin models, Evaluating the role of KLF4, Statistics

Lung hydroxyproline at day 21: Hydroxyproline as total-lung collagen endpoint; Figure 6C shows individual mice, mean ± SEM; caption reports n = 5–8 per group across the figure and 2-way ANOVA with Tukey multiple comparisons. — Figure 6A-C and caption; Results: Therapeutic administration of APTO-253 protects mice from bleomycin-induced pulmonary fibrosis; Methods: Mice, Bleomycin models, Evaluating the role of KLF4, Statistics

Bleomycin + APTO-253 · Figure 6A-C and caption; Results: Therapeutic administration of APTO-253 protects mice from bleomycin-induced pulmonary fibrosis; Methods: Mice, Bleomycin models, Evaluating the role of KLF4, Statistics

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 916151-99-0
Applications MTF-1 inhibitor
Formula C22H14FN5
Molecular Weight 367.38
Synonyms APTO-253
SMILES
CC1=C(C2=C(N1)C=CC(=C2)F)C3=NC4=C5C=CC=NC5=C6C(=C4N3)C=CC=N6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 72 mg/mL (195.98 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

LOR-253 Research References

  1. [1] Penke LR, Speth JM, Huang SK, et al. KLF4 is a therapeutically tractable brake on fibroblast activation that promotes resolution of pulmonary fibrosis JCI Insight (2022). PMID: 35852857 DOI: 10.1172/jci.insight.160688 Source material
  2. [2] Chandrasekaran B, Tyagi B, Tyagi A, et al. Mechanistic role of metal-responsive transcription factor-1 (MTF1) in cadmium-induced prostate carcinogenesis Int J Biol Sci (2025). PMID: 40520016 DOI: 10.7150/ijbs.110174 Source material
  3. [3] Tsai CY, Sun S, Zhang H, et al. APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency Mol Cancer Ther (2018). PMID: 29626126 DOI: 10.1158/1535-7163.mct-17-0834 Source material

Publications

1 publication citing this product

  1. Balaji Chandrasekaran, .et al. , Int J Biol Sci, 2025, May 27;21(8):3614-3630 PMID: 40520016

Added to your cart

View Cart Checkout
Loading...